Acerca de

There are no FDA approved products explicitly approved for the treatment of nail psoriasis.  Although some biologics (adalimumab, infliximab, etanercept, ustekinumab) and other systemic therapies (apremilast, acitretin, methotrexate) are effective for nail psoriasis, they are approved for the treatment of moderate-to-severe skin psoriasis and psoriatic arthritis and are typically limited to use for patients with extensive skin or joint involvement.   Many of these medication are not covered by insurance unless pateints also have extensive skin or joint involvement.  For patients with psoriasis limited to the nails or with low body surface area (BSA) involvement, topical and injectable therapies (corticosteroids, calcipotriol, retinoids, tacrolimus) are preferred due to their favorable safety profile but have limited efficacy.  Intralesional corticosteroid injection is used for nail psoriasis but can cause pain on injection, skin atrophy, depigmentation, cyst formation, subungual hemorrhage, tendon rupture, and secondary infection.  A topical medication that is effective with a favorable safety profile would fulfill an unmet medical need.